Skip to main content
Erschienen in: Uro-News 3/2019

03.03.2019 | Prostatakarzinom | Zertififizierte Fortbildung

Behandlungsmöglichkeiten in der Uroonkologie

Neue Systemtherapien und Studien beim Prostatakarzinom

verfasst von: Dr. med. univ. Sebastian Hofbauer, Hans Krause, Thorsten Schlomm, Maria De Santis

Erschienen in: Uro-News | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Systemtherapie beim Prostatakarzinom war lange darauf limitiert, die Testosteronwirkung auf die Tumorzellen zu hemmen. Nun könnten Therapie- und Therapiesequenzauswahl komplexer — das inkurable metastasierte Prostatakarzinom dafür immer mehr zur chronischen Erkrankung werden.
Literatur
1.
Zurück zum Zitat Tannock IF. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502–12CrossRef Tannock IF. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502–12CrossRef
2.
Zurück zum Zitat Karantanos T. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2015; 67: 470–9CrossRef Karantanos T. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2015; 67: 470–9CrossRef
3.
Zurück zum Zitat de Bono JS et al. Abirateron and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364: 1995–2005CrossRef de Bono JS et al. Abirateron and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364: 1995–2005CrossRef
4.
Zurück zum Zitat Fizazi K et al. Abirateron plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017; 377: 352–60CrossRef Fizazi K et al. Abirateron plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017; 377: 352–60CrossRef
5.
Zurück zum Zitat Beer TM et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371: 424–33CrossRef Beer TM et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371: 424–33CrossRef
6.
Zurück zum Zitat Hussain M. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018; 378: 2465–74CrossRef Hussain M. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018; 378: 2465–74CrossRef
7.
Zurück zum Zitat Smith MR et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018; 378: 1408–18CrossRef Smith MR et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018; 378: 1408–18CrossRef
8.
Zurück zum Zitat Teply BA et al. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol. 2018; 19: 76–86CrossRef Teply BA et al. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol. 2018; 19: 76–86CrossRef
9.
Zurück zum Zitat Kantoff PW et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411–22CrossRef Kantoff PW et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411–22CrossRef
10.
Zurück zum Zitat Kwon ED et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014; 15: 700–12CrossRef Kwon ED et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014; 15: 700–12CrossRef
11.
Zurück zum Zitat Topalian SL et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443–54CrossRef Topalian SL et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443–54CrossRef
12.
Zurück zum Zitat De Bono JS et al. KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. American Society of Clinical Oncology; 2018; 36: 5007CrossRef De Bono JS et al. KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. American Society of Clinical Oncology; 2018; 36: 5007CrossRef
13.
Zurück zum Zitat Le DT et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357: 409–13CrossRef Le DT et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357: 409–13CrossRef
14.
Zurück zum Zitat James ND et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016; 387: 1163–77CrossRef James ND et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016; 387: 1163–77CrossRef
15.
Zurück zum Zitat Sweeney CJ et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015; 373: 737–46CrossRef Sweeney CJ et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015; 373: 737–46CrossRef
16.
Zurück zum Zitat de Bono JS et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376: 1147–54CrossRef de Bono JS et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376: 1147–54CrossRef
17.
Zurück zum Zitat Gillessen S et al. 814PPlatinum-based therapy in men with metastatic castration resistant prostate (mCRPC) with or without DNA repair defects: A multicentre retrospective analysis. Ann Oncol. 2018; http://doi.org/czxj Gillessen S et al. 814PPlatinum-based therapy in men with metastatic castration resistant prostate (mCRPC) with or without DNA repair defects: A multicentre retrospective analysis. Ann Oncol. 2018; http://​doi.​org/​czxj
18.
Zurück zum Zitat Smith MR et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012; 379: 39–46CrossRef Smith MR et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012; 379: 39–46CrossRef
19.
Zurück zum Zitat Parker C et al. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. N Engl J Med. 2013; 369: 213–23CrossRef Parker C et al. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. N Engl J Med. 2013; 369: 213–23CrossRef
20.
Zurück zum Zitat Mateo J et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015; 373: 1697–708CrossRef Mateo J et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015; 373: 1697–708CrossRef
Metadaten
Titel
Behandlungsmöglichkeiten in der Uroonkologie
Neue Systemtherapien und Studien beim Prostatakarzinom
verfasst von
Dr. med. univ. Sebastian Hofbauer
Hans Krause
Thorsten Schlomm
Maria De Santis
Publikationsdatum
03.03.2019
Verlag
Springer Medizin
Erschienen in
Uro-News / Ausgabe 3/2019
Print ISSN: 1432-9026
Elektronische ISSN: 2196-5676
DOI
https://doi.org/10.1007/s00092-019-2061-0

Weitere Artikel der Ausgabe 3/2019

Uro-News 3/2019 Zur Ausgabe